This is a working overview of copper tripeptide, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-01-15 and is reviewed periodically as new material appears.
GHK-Cu is the copper-binding complex formed by the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The free peptide is usually written as GHK, and the complex is written as GHK-Cu or Cu-GHK. The sequence was identified in human plasma and later detected in saliva and urine. Its name comes from the single-letter codes of glycine, histidine and lysine. The complex is widely described as a naturally occurring carrier of copper in blood rather than as a free peptide with its own hormonal role.
Copper binds to the peptide through the histidine imidazole nitrogen and the terminal amino group, forming a stable square-planar complex. Binding constants reported for copper(II) with GHK are high, so the peptide competes effectively for copper in solution. The complex absorbs visible light, which gives solutions a blue to violet colour. Whether the metal-free peptide has a distinct biological function of its own is still an open question; some work treats it mainly as a copper delivery vehicle, while other work reports peptide-specific effects.
The compound was first isolated from human plasma in the 1970s by Loren Pickart, who later described copper-binding activity in liver and other tissues. Early reports focused on its presence in blood and its ability to carry copper between proteins. Commercial and cosmetic use of the term 'copper peptide' has since broadened, and labels rarely distinguish GHK-Cu from other copper-binding fragments. This naming overlap makes literature searching harder, because cosmetic ingredient lists, supplier catalogues and laboratory papers use different vocabularies for the same molecule.
Quality specifications for research material commonly state peptide purity, copper stoichiometry, counter-ion identity, and residual water content. Frequent counter-ions include acetate and trifluoroacetate, which differ in mass and in their effect on solubility and handling. Whether batch-to-batch differences in reported responses trace to these parameters or to assay conditions remains an open question, since published comparisons rarely control for all of them at once. Independent verification therefore normally pairs a purity measurement with an elemental copper measurement on the same lot.
Practical handling notes centre on limiting exposure to water, oxygen, and repeated temperature cycling. Weighed powder is often equilibrated to room temperature before opening to avoid condensation on the solid. Working solutions are typically divided into single-use aliquots and frozen rather than stored refrigerated for long periods. Reported shelf lives vary widely between laboratories, and no single set of conditions is universally treated as a reference standard, which complicates direct comparison of published stability figures.
| Property | Value | Notes |
|---|---|---|
| Sequence | Gly-His-Lys | Three amino acids; histidine supplies the main copper-binding nitrogen |
| Bound metal | Copper(II) | Coordination is described as square-planar around the metal centre |
| Appearance | Blue to violet solid | Colour originates from copper d-d electronic transitions |
| Solubility class | Freely soluble in water | Aqueous solutions are often slightly acidic |
| Common synonyms | Copper tripeptide, Cu-GHK | Ingredient lists may say only 'copper peptide' without giving the sequence |
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry to confirm the expected mass. Copper content is measured separately by inductively coupled plasma optical emission spectrometry or atomic absorption spectroscopy, because the peptide assay alone does not establish the metal-to-peptide ratio. Visible spectroscopy provides a rapid check on complex integrity through the absorption band in the visible region. Agreement between the peptide assay and the copper assay is the practical test of whether a sample is the intended complex rather than a mixture.
Aqueous solutions of GHK-Cu are less stable than the dry powder. The peptide backbone is vulnerable to hydrolysis at extreme pH, and copper can be stripped from the complex by strong chelating agents such as EDTA or citrate. Oxidising agents and high concentrations of ascorbic acid can reduce copper(II) and change the complex, which is one reason formulators often keep such ingredients in separate phases. How quickly these changes occur under real storage conditions depends on pH, buffer, temperature and packaging, and quantitative data on the subject are limited.
Dry material is normally held cold, commonly at -20 °C for long-term storage and 2 to 8 °C for working quantities, protected from light and moisture. Vials should be allowed to reach room temperature before opening so that condensation does not form on the powder. In liquid formulations the complex is generally kept near neutral to slightly acidic pH, because strongly alkaline conditions favour precipitation of copper hydroxide. Antioxidants or chelate-stabilising excipients are often added, though the specific approaches are proprietary and rarely published in detail.
Analytical confirmation usually combines a separation method with a copper-specific measurement. Liquid chromatography or mass spectrometry establishes peptide identity and purity, while an elemental measurement quantifies the metal content. A frequent misconception is that any blue solution contains an intact copper peptide complex; color alone does not confirm structure, because free copper salts and degraded mixtures can also appear colored. Literature on efficacy is mixed, with in vitro findings often more dramatic than human evidence, and reviews note small sample sizes and short follow-up. Open questions include optimal concentration, skin penetration, and long-term effects.
Proposed mechanisms for copper peptide activity center on delivery of copper ions to cells and on peptide fragments acting as signaling molecules. Copper is a cofactor for enzymes involved in collagen cross-linking and antioxidant defense, and the peptide may improve its availability at target sites. Separately, the tripeptide and its breakdown products have been reported to influence gene expression in cultured fibroblasts. Much of this evidence comes from laboratory cell cultures and animal models rather than controlled human trials. The relative contribution of the copper ion and the peptide sequence is therefore not fully settled.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry. Copper content is measured separately by techniques such as inductively coupled plasma mass spectrometry or atomic absorption. Amino acid analysis confirms the peptide sequence after hydrolysis. Because the metal and the peptide can be quantified independently, a complete certificate of analysis normally reports both values rather than a single purity figure. This separation of measurements is important when comparing suppliers.
Solid GHK-Cu appears as a blue to blue-violet powder, and the colour is a direct consequence of copper coordination. The complex dissolves readily in water and in many polar solvents, while the free peptide behaves differently. Solubility in nonpolar media is low, which limits its use in oil-based systems. Solutions are typically prepared fresh because the dissolved form is more exposed to hydrolysis and to loss of the metal ion than the dry powder. Working concentrations are usually low, and preparation notes often specify the solvent and the order of addition.
Dry material is typically held at low temperature, often around minus twenty degrees Celsius, and protected from moisture and light. Copper complexes can release their metal ion under acidic conditions or in the presence of competing chelators. Hydrolysis of the peptide backbone is a slower but real pathway, and the histidine residue is susceptible to oxidation over long periods. Stability statements therefore depend on formulation, pH, and container, and they should be read as conditional rather than absolute.
As part of the Synthetic Yeast 2.0 project, various research groups around the world have participated in a project to synthesise synthetic yeast genomes, and through this process, optimise the genome of the model organism Saccharomyces cerevisiae. The Yeast 2.0 project applied various DNA assembly methods that have been discussed above, and in March 2014, Jef Boeke of the Langone Medical Centre at New York University, revealed that his team had synthesized chromosome III of S. cerevisiae. The procedure involved replacing the genes in the original chromosome with synthetic versions and the finished synthetic chromosome was then integrated into a yeast cell. It required designing and creating 273,871 base pairs of DNA – fewer than the 316,667 pairs in the original chromosome. In March 2017, the synthesis of 6 of the 16 chromosomes had been completed, with synthesis of the others still ongoing.
CooA is a heme-containing transcription factor that responds to the presence of carbon monoxide. This protein forms homodimers and is a homolog of cAMP receptor protein. The most well-studied CooA homolog comes from Rhodospirillum rubrum (RrCooA), but the homolog from Carboxydothermus hydrogenoformans (ChCooA) has also been characterized. The main structural difference between these homologs lies in ferric heme coordination. In RrCooA, the ferric heme iron is ligated by a cysteine and the amine of the N-terminal proline; in the ferrous state, a ligand switch occurs in which a histidine replaces the thiolate. In contrast, ChCooA features histidine and the N-terminal amine as ligands in both ferric and ferrous states.
On 1 December 1978, the Health and Safety Executive announced their intention to prosecute the university for breach of safety legislation. The case was heard in October 1979 at Birmingham Magistrates' Court. Although the source of infection was traced, the mode and cause of transmission was not. Evidence presented by several internationally recognised experts, including Kevin McCarthy, Allan Watt Downie and Keith R. Dumbell, showed that airborne transmission from the laboratory to the telephone room where Parker was supposedly infected was highly improbable. The experts calculated that it would require 53,700 litres (11,812 imp gal) of virus fluid to have been aspirated (meaning, in this context, removed by suction of fluid and cells through a needle) and it would take 20,000 years for one particle to travel to the telephone room at the rate the fluid was aspirated. It was additionally found that although the Shooter Inquiry noted the poor state of the duct sealing in the laboratory, this was caused after the outbreak by engineers fumigating the laboratory and ducts. The university was found not guilty of causing Parker's death.
The citric acid cycle is regulated mainly by the availability of key substrates, particularly the ratio of NAD+ to NADH and the concentrations of calcium, inorganic phosphate, ATP, ADP, and AMP. Citrate – the ion that gives its name to the cycle – is a feedback inhibitor of citrate synthase and also inhibits PFK, providing a direct link between the regulation of the citric acid cycle and glycolysis.
Sources: en.wikipedia.org
In 1969, after completing her medical training, she became a lecturer at the Department of Bacteriology and Immunology in Glasgow's Western Infirmary teaching hospital. While working at the hospital she carried out research on the role of intra-epithelial lymphocytes in intestinal immunity, receiving her PhD in 1974. In 1975, she was appointed as a senior lecturer at the University of Edinburgh, also becoming a consultant at the Gastrointestinal Unit at the Western General Hospital in Edinburgh. In 1987 she was appointed to a personal professorship in gastroenterology. From 1991 to 1994 she was head of the Department of Medicine at the university. She published more than 250 papers in peer-reviewed academic journals, published three books and contributed chapters to many other books. Her research provided new insights into the mechanisms responsible for Crohn's and coeliac diseases which led to significant advances in the therapy of these conditions. She also carried out significant research on oral tolerance. She served on the Committee on Safety of Medicines, the Medical Research Council Gene Therapy Advisory Board, and the Spongiform Encephalopathy Advisory Committee. At the time of her death she was president of the Society for Mucosal Immunology. She was a consultant providing advice and training to the International Centre for Diarrhoeal Disease Research in Bangladesh.
Adenylyl cyclase: When a ligand binds to the ADRB-1 receptor, the alpha-subunit of the heterotrimeric G-protein gets activated, which in turn, activates the enzyme adenylyl cyclase. Adenylyl cyclase then catalyzes the conversion of ATP to cyclic AMP (cAMP), which activates downstream effectors such as Protein Kinase A (PKA). cAMP activation of PKA: cAMP generated by adenylyl cyclase activates PKA, which then phosphorylates numerous downstream targets such as ion channels, other enzymes, and transcription factors . Beta-arrestins: Activation of the ADRB-1 receptor can lead to the recruitment of Beta-arrestins, which are used to activate signaling pathways independent of G-proteins. An example of an independent pathway is the MAPK (mitogen-activated protein kinase) pathways. Calcium signaling: ADRB-1 signaling also activates the Gq/11 family of G proteins, which is a subfamily of heterotrimeric G proteins that activates phospholipase C (PLC). PLC cleaves phosphatidylinositol 4,5-bisphosphate (PIP2) into the second messengers inositol 1,4,5-triphosphate (IP3) and diacylglycerol (DAG). IP3 binds to IP3 receptors on the endoplasmic reticulum, which then leads to the release of calcium ions (Ca2+) into the cytoplasm, resulting in the activation of downstream signaling pathways.
Carnitine is an essential cofactor for mitochondrial transport of long‑chain fatty acids (a major lipid class) into the matrix for β‑oxidation. gamma-aminobutyric acid is a neurotransmitter. 5-HTP (5-hydroxytryptophan) is used for experimental treatment of depression. L-DOPA (L-dihydroxyphenylalanine) for Parkinson's treatment, Eflornithine inhibits ornithine decarboxylase and used in the treatment of sleeping sickness. Canavanine, an analogue of arginine found in many legumes is an antifeedant, protecting the plant from predators. Mimosine found in some legumes, is another possible antifeedant. This compound is an analogue of tyrosine and can poison animals that graze on these plants. However, not all of the functions of other abundant nonstandard amino acids are known.
Antidotes are agents that can neutralise the effects of a poison or toxin. Antidotes counteract the effects of toxins in many ways, such as by blocking the absorption of the toxin, binding and neutralising the poison, opposing the toxin's end-organ function, or blocking the toxin's conversion to more hazardous metabolites. In addition to lowering the amount of free or active poison present, antidote delivery may also lessen the toxin's effects on organs through competitive inhibition, receptor blockage, or direct antagonistic interaction. The therapeutic index or ratio (TD50/ED50), which is the ratio of the toxic dosage (TD) or fatal dose (LD) to the effective dose (ED), determines the level of safety associated with a substance.
3D bioprinting generally follows three steps: pre-bioprinting, bioprinting, and post-bioprinting. Pre-bioprinting is the process of creating a model that the printer will later create and choosing the materials that will be used. One of the first steps is to obtain a biopsy of the organ, to sample cells. Common technologies used for bioprinting are computed tomography (CT) and magnetic resonance imaging (MRI). To print with a layer-by-layer approach, tomographic reconstruction is done on the images. The now-2D images are then sent to the printer to be made. Once the image is created, certain cells are isolated and multiplied. These cells are then mixed with a special liquefied material that provides oxygen and other nutrients to keep them alive. This aggregation of cells does not require a scaffold, and is required for placing in the tubular-like tissue fusion for processes such as extrusion.
Sources: en.wikipedia.org
The letters GHK are the one-letter codes for glycine, histidine and lysine, the three amino acids in the peptide. The suffix Cu indicates that the peptide is bound to a copper ion, normally copper(II).
The free tripeptide and its copper complex have been measured in human plasma, saliva, urine and some tissue extracts. Reported concentrations vary widely between studies, and the role of the complex in normal physiology remains partly unresolved.
The plain peptide lacks the metal, so its charge, colour and binding behaviour differ. The copper complex is blue and carries a bound copper ion, while the metal-free form is colourless and has different solution chemistry.
Inductively coupled plasma mass spectrometry or atomic absorption spectroscopy gives total copper after acid digestion. Combining that value with a peptide concentration from chromatography or amino acid analysis yields the metal-to-peptide ratio.